



# INVESTIGATING A QUANTITATIVE METRIC FOR ESTIMATING PROPORTIONAL HAZARDS IN TIME-TO-EVENT OUTCOMES –A SIMULATION STUDY USING REAL-WORLD DATA

Soichi Takeishi, MD, Tatsuo Inoue, MD

WCN24-AB-297

Department of Diabetes, Inuyama Chuo General Hospital

## Background

- Cox proportional hazard model (Cox) with a binary covariate is used widely to assess the effect of intervention (I) on cardiorenal event risks.
- As Kaplan-Meier (KM) curves of I and control (C) approximate proportional hazards (PH), quality of data analyzed using Cox becomes high.
- Quantitative methods for assessing PH are unknown.
- If PH can be quantitatively estimated from published KM curves of I and C, data reliability is easier to assess.
- We conducted a simulation study using real-world data for quantitative evaluation of PH.


## Research design & Methods

- We used glucose levels (GL) measured at 15-minute intervals using continuous glucose monitoring (CGM: FreeStyle Libre Pro) as time-to-event data.
- This data was selected for two reasons. Firstly, there is no censoring; secondly, observation periods and timepoints are unified.
- We analyzed GL for 100 “outpatients with Type 2 diabetes” (pT2D), measured by CGM over 24-h for 13 days (from 0 AM on Day 2 to 0 AM on Day 15 [CGM attachment: Day 1]).
- The pT2D did not change their treatments throughout the CGM observation period.
- We analyzed cumulative survival rates [S(t)] using Cox [S(t)Cox] and KM method [S(t)KM] for 13 endpoints where time to event was expected to be delayed by I, compared to C.
- Observations were done at all GL measurement.
- The GL value at each of these timepoints is estimated to be identical to the GL values in the preceding 1–14 minutes for calculating metrics proposed later.
- We defined “ $-\text{Loge}(\text{S(t)KM for I}) [\text{Log}^*e, \text{‘Napier’s constant’}] \div -\text{Loge}(\text{S(t)KM for control [C]})$ ” as “e hazard ratio” (eHR).
- We proposed a quantitative metric, “absolute value of difference between eHR and HR” ( $|\text{eHR} - \text{HR}|$ ) to estimate PH for time-to-event outcomes.
- “ $\Delta \text{Loge}(-\text{Loge}(\text{S(t)Cox})) [\text{C} - \text{I}]$ ” ( $\Delta \text{log} - \text{logS(t)Cox}$ ) is constant at every observation time because Cox has a fundamental PH. Hence, we proposed a metric, absolute value of coefficient of variation (CV) of 18720 ( $60 \times 24 \times 13$ ) “ $\Delta \text{Loge}(-\text{Loge}(\text{S(t)KM})) [\text{C} - \text{I}]$  at one-minute intervals [ $\Delta \text{log} - \text{logS(t)KM}$ ]” ( $|\text{CV}| \Delta \text{log} - \text{logKM}$ ) for estimating PH.
- Since we thought lower CV of 18720 “ $\Delta^*1 - \text{S(t)KM}^* [\text{C} - \text{I}]$  at one-minute intervals [ $\Delta \text{KM}$ ]” ( $\text{CV} \Delta \text{KM}$ ) better satisfy PH, we proposed a metric,  $\text{CV} \Delta \text{KM}$ , to visually assess PH from KM curves.
- Corresponding with the concept of Restricted Mean Survival Time (RMST), we propose a metric, RMST related index (RMSTrI), as sum of 18720  $\Delta \text{KM}$ . Gregson J, et al. J Am Coll Cardiol. 2019; 74: 2102-2112.

➤ Primary endpoints

A correlation between  $|\text{eHR} - \text{HR}|$  and  $|\text{CV}|$  of  $\Delta \text{log} - \text{log} (\text{KM})$ .

## Results and Discussions



| Characteristic         | Values        |
|------------------------|---------------|
| N (Male / Female)      | 100 (60 / 40) |
| Age, years             | 69.5 ± 13.4   |
| BMI, kg/m <sup>2</sup> | 24.2 ± 4.1    |
| HbA1c, %               | 8.0 ± 1.5     |

Table 1: The characteristics of patients providing the CGM data

Data are shown as mean ± standard deviation.

BMI, body mass index; HbA1c, hemoglobin A1c

| Response variable                                         | Binary covariate<br>(Intervention / Control) | HR   | 1-HR | eHR  | eHR-HR | CV Δlog–<br>logKM, % | CVΔKM, % | RMSTrI  |
|-----------------------------------------------------------|----------------------------------------------|------|------|------|--------|----------------------|----------|---------|
| First time of <70 mg/dL                                   | HbA1c>8% / HbA1c<8%                          | 0.27 | 0.73 | 0.27 | 0.00   | 11.06                | 10.19    | 7209.82 |
| First time of <60 mg/dL                                   | HbA1c>8% / HbA1c<8%                          | 0.11 | 0.89 | 0.11 | 0.00   | 7.32                 | 12.95    | 6652.06 |
| First time of >250 mg/dL                                  | HbA1c<8% / HbA1c>8%                          | 0.40 | 0.60 | 0.37 | 0.03   | 13.74                | 13.07    | 4910.10 |
| First time of >300 mg/dL                                  | HbA1c<8% / HbA1c>8%                          | 0.30 | 0.70 | 0.36 | 0.07   | 21.22                | 17.61    | 7658.46 |
| First time of >250 mg/dL                                  | CV<36% / CV>36%                              | 0.80 | 0.20 | 0.56 | 0.24   | 65.05                | 60.79    | 1996.85 |
| First time of >300 mg/dL                                  | CV<36% / CV>36%                              | 0.56 | 0.44 | 0.47 | 0.09   | 45.32                | 36.44    | 4058.29 |
| First time of >350 mg/dL                                  | CV<36% / CV>36%                              | 0.84 | 0.16 | 0.80 | 0.04   | 143.56               | 99.27    | 1080.91 |
| Achievement of time out of<br>70-180 mg/dL>30% of 13 days | CV<36% / CV>36%                              | 0.75 | 0.25 | 0.64 | 0.11   | 751.81               | 791.86   | 153.01  |
| Achievement of time out of<br>54-250 mg/dL>6% of 13 days  | CV<36% / CV>36%                              | 0.45 | 0.55 | 0.39 | 0.06   | 82.32                | 78.40    | 3301.91 |
| First time of >250 mg/dL                                  | CV<30% / CV>30%                              | 0.86 | 0.14 | 0.74 | 0.11   | 69.96                | 59.05    | 1678.78 |
| First time of >300 mg/dL                                  | CV<30% / CV>30%                              | 0.55 | 0.45 | 0.49 | 0.06   | 46.77                | 35.08    | 3669.81 |
| Achievement of time above<br>180 mg/dL>25% of 13 days     | HbA1c<8% / HbA1c>8%                          | 0.23 | 0.77 | 0.26 | 0.02   | 59.47                | 44.44    | 5568.10 |
| Achievement of time above<br>250 mg/dL>5% of 13 days      | HbA1c<8% / HbA1c>8%                          | 0.21 | 0.79 | 0.24 | 0.03   | 23.72                | 29.79    | 7615.51 |

Figure 2: The metrics for the 13 endpoints.

CV: coefficient of variation

r=0.62, p=0.02    r=0.98, p<0.001

r=0.86, p<0.001

## Contact information

Soichi Takeishi, MD    E-mail: souichi19811225@yahoo.co.jp  
Inuyama-city, Aichi,    Phone: +81-568-62-8111  
484-8511, JAPAN    Fax: +81-586-48-9289

## Conclusion

- Using  $|\text{eHR} - \text{HR}|$  as a quantitative metric, PH may be estimated from published KM curves.
- Catching variability of difference in S(t)KM at the same timepoint between I and C visually, PH may be estimated.
- Area between KM curves of I and C may reflect  $|1 - \text{HR}|$ .